|
| |
 |
| |
|
| |
| Latest News |
Data Presented From Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
>>more
|
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
>>more
|
Lilly Names New Business Leaders
>>more
|
|
|
|
 |
| |
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE:LLY), is committed to advancing oncology
care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with
a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology.
ImClone has several investigational monoclonal antibodies in various stages of clinical development. ImClone's research
and clinical development capabilities
are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art
FDA-approved manufacturing facilities provide it with one of the largest biologic manufacturing capacities in the world.
ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company on November 24, 2008. Read the press release
Additional information about Lilly is available at www.lilly.com
|
|
